Novo Nordisk surges as Hims & Hers ditches copycat weight-loss pill

(Sharecast News) - Shares of Danish pharmaceuticals firm Novo Nordisk surged on Monday after US telehealth company Hims & Hers said it had ditched plans to sell its own version of the Wegovy weight-loss drug. On a post on X on Saturday, the company said: "Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry.

"As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalised care."

Hims & Hers was facing legal action from Novo Nordisk and the US Food and Drug Administration.

At 0850 GMT, Novo Nordisk shares were 8.4% higher at DKK320.15.